BACKGROUND: High-grade astrocytomas are rare in young children, but have been reported to have a better prognosis than similar tumors in older patients. PROCEDURE: We retrospectively reviewed the clinical characteristics, survival, and long-term sequelae for patients younger than 3 years old with high-grade astrocytoma, treated at a single institution between 1984 and 2005. RESULTS: Sixteen patients were included. Histology included anaplastic astrocytoma (n = 9), glioblastoma multiforme (n = 5), and malignant glioma (n = 2). All patients underwent biopsy or resection, followed by chemotherapy. Six patients received scheduled irradiation and six were irradiated at the time of disease progression. Ten patients are alive at a median follow-up of 11.6 years (range, 1.7-21.6 years). 5-year overall survival (OS) was 66.3% (SE 12.2%), and 5-year event-free survival (EFS) was 28.6% (SE 12.1%). Age at diagnosis was a significant predictor of the hazard of death in a Cox model (HR 2.871, 95%CI 1.015-8.123). Gender and histology did not predict OS or EFS. Trends toward improved OS were detected for patients with hemispheric tumors and those undergoing complete resection. All evaluable survivors (n = 9) had some neurocognitive impairment, with estimated overall cognitive ability ranging from significantly delayed to average; all survivors attending school (n = 5) performed below grade level on achievement testing. Seven of nine evaluable survivors had endocrine dysfunction. CONCLUSIONS: Young children with high-grade astrocytoma have better long-term overall survival than older patients, but recurrence is common, and most children require irradiation. Long-term complications are frequent and often severe. 2007 Wiley-Liss, Inc
BACKGROUND: High-grade astrocytomas are rare in young children, but have been reported to have a better prognosis than similar tumors in older patients. PROCEDURE: We retrospectively reviewed the clinical characteristics, survival, and long-term sequelae for patients younger than 3 years old with high-grade astrocytoma, treated at a single institution between 1984 and 2005. RESULTS: Sixteen patients were included. Histology included anaplastic astrocytoma (n = 9), glioblastoma multiforme (n = 5), and malignant glioma (n = 2). All patients underwent biopsy or resection, followed by chemotherapy. Six patients received scheduled irradiation and six were irradiated at the time of disease progression. Ten patients are alive at a median follow-up of 11.6 years (range, 1.7-21.6 years). 5-year overall survival (OS) was 66.3% (SE 12.2%), and 5-year event-free survival (EFS) was 28.6% (SE 12.1%). Age at diagnosis was a significant predictor of the hazard of death in a Cox model (HR 2.871, 95%CI 1.015-8.123). Gender and histology did not predict OS or EFS. Trends toward improved OS were detected for patients with hemispheric tumors and those undergoing complete resection. All evaluable survivors (n = 9) had some neurocognitive impairment, with estimated overall cognitive ability ranging from significantly delayed to average; all survivors attending school (n = 5) performed below grade level on achievement testing. Seven of nine evaluable survivors had endocrine dysfunction. CONCLUSIONS: Young children with high-grade astrocytoma have better long-term overall survival than older patients, but recurrence is common, and most children require irradiation. Long-term complications are frequent and often severe. 2007 Wiley-Liss, Inc
Authors: Douglas R Strother; Lucie Lafay-Cousin; James M Boyett; Peter Burger; Patricia Aronin; Louis Constine; Patricia Duffner; Mehmet Kocak; Larry E Kun; Marc E Horowitz; Amar Gajjar Journal: Neuro Oncol Date: 2013-12-12 Impact factor: 12.300
Authors: Barbara S Paugh; Chunxu Qu; Chris Jones; Zhaoli Liu; Martyna Adamowicz-Brice; Junyuan Zhang; Dorine A Bax; Beth Coyle; Jennifer Barrow; Darren Hargrave; James Lowe; Amar Gajjar; Wei Zhao; Alberto Broniscer; David W Ellison; Richard G Grundy; Suzanne J Baker Journal: J Clin Oncol Date: 2010-05-17 Impact factor: 44.544
Authors: Ching-Hon Pui; Amar J Gajjar; Javier R Kane; Ibrahim A Qaddoumi; Alberto S Pappo Journal: Nat Rev Clin Oncol Date: 2011-06-28 Impact factor: 66.675
Authors: Eduard H Panosyan; Dan R Laks; Michael Masterman-Smith; Jack Mottahedeh; William H Yong; Timothy F Cloughesy; Jorge A Lazareff; Paul S Mischel; Theodore B Moore; Harley I Kornblum Journal: Pediatr Blood Cancer Date: 2010-10 Impact factor: 3.167
Authors: Federico Sánchez-Herrera; Eduardo Castro-Sierra; Luis Felipe Gordillo-Domínguez; Miguel Angel Vaca-Ruiz; Blanca Santana-Montero; Mario Perezpeña-Diazconti; Vicente González-Carranza; Samuel Torres-García; Fernando Chico-Ponce de León Journal: Childs Nerv Syst Date: 2009-01-16 Impact factor: 1.475
Authors: Juan C Espinoza; Kelley Haley; Neha Patel; Girish Dhall; Sharon Gardner; Jeffrey Allen; Joseph Torkildson; Albert Cornelius; Rod Rassekh; Antranik Bedros; Morris Etzl; James Garvin; Kamnesh Pradhan; Robin Corbett; Michael Sullivan; Geoffrey McGowage; Dagmar Stein; Rama Jasty; Stephen A Sands; Lingyun Ji; Richard Sposto; Jonathan L Finlay Journal: Pediatr Blood Cancer Date: 2016-06-22 Impact factor: 3.167